Comment on: Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report

Dear Editor,

With great interest, I went through the article titled “Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report” by Sarpangala et al.[1] The authors have managed a tricky case in which multiple etiologies had to be ruled out. I have a few observations. The authors have mentioned that there was clinical improvement 3 days following institution of systemic anti-viral therapy. However, in the clinical fundus photograph provided, 3 days following therapy, it seems as if the vascular sheathing along the superotemporal vein has actually increased (worsened) following anti-viral therapy. It would be good to know the duration between initial presentation and institution of systemic therapy. A longer duration between initial presentation and start of therapy might have led to an increase in the vascular sheathing. It will also be interesting to know if there was an increase in visual acuity and decrease in vitreous haze 3 days after starting anti-viral therapy.

Ocular involvement in sarcoidosis is present in 80% of the cases and is frequently manifested before the diagnosis of systemic disease.[2] Posterior segment involvement in sarcoidosis can take the form of retinal vasculitis, perivenous infiltrates with characteristic candle wax drippings, choroiditis patches, and optic nerve granuloma. Absence of characteristic sarcoid lesions does not rule out ocular sarcoidosis. The definitive diagnosis of ocular sarcoidosis is based on biopsy-proven lesions compatible with clinical signs of uveitis.[3] Investigations supportive of ocular sarcoidosis include raised serum angiotensin-converting enzyme (ACE)/lysozyme levels, chest X-ray or high-resolution computed tomography suggestive of bilateral peribilar lymphadenopathy, abnormal liver enzyme tests, and negative tuberculin test in a BCG-vaccinated patient.[3] The present case had raised serum ACE levels. Other laboratory tests supportive of ocular sarcoidosis could have been performed before ruling it out as a possible etiology.
In addition, the present case had raised serum homocysteine levels. Elevated serum homocysteine is itself an independent risk factor associated with retinal vein occlusions.[3] Raised serum homocysteine levels can also be associated with systemic thrombosis. The chances of raised homocysteine level as the possible etiology for central retinal vein occlusion in the present case seem highly unlikely. However, as elevated levels of serum homocysteine are associated with thrombotic lesions, treatment should be started to lower its level to prevent any systemic complications in the future.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Pradeep K Panigrahi
Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, Siksha O Anusandhan (Deemed to be) University, Bhubaneswar, Odisha, India

Correspondence to: Dr. Pradeep K Panigrahi, Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, Siksha O Anusandhan (Deemed to be) University, 8-Kalinga Nagar, Bhubaneswar - 751 003, Odisha, India. E-mail: doc.pkp25@gmail.com

References
1. Sarpangala S, George NM, Kamath YS, Kulkarni C. Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic-A case report. Indian J Ophthalmol 2021;69:2532-35.
2. Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: New diagnostic modalities and treatment. Curr Opin Pulm Med 2017;23:458-67.
3. Minniti G, Calevo MG, Giannattasio A, Camiciione P, Armani U, Lorini R, et al. Plasma homocysteine in patients with retinal vein occlusion. Eur J Ophthalmol 2014;24:735-43.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Cite this article as: Panigrahi PK. Comment on: Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report. Indian J Ophthalmol 2022;70:343-4.
© 2021 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow